Cargando…

Effectiveness of enfuvirtide in a cohort of highly antiretroviral-experienced HIV-1-infected patients in Mexico

BACKGROUND: Treatments in patients with multidrug resistance often involve the use of multiple agents with partial antiviral activity and overlapping metabolic toxicities. Enfuvirtide is therefore a welcome addition to the antiretroviral management of patients with multiclass resistant virus, given...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huerta-García, Gloria, Chavez-García, Marcelino, Mata-Marín, José Antonio, Sandoval-Ramírez, Jorge, Domínguez-Hermosillo, Juan, Rincón-Rodríguez, Ana Lourdes, Gaytán-Martínez, Jesús
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4280743/ https://www.ncbi.nlm.nih.gov/pubmed/25553058 http://dx.doi.org/10.1186/s12981-014-0040-9

Ejemplares similares

Effectiveness and risk factors for virological outcome of darunavir-based therapy for treatment-experienced HIV-infected patients
por: Mata-Marín, José Antonio, et al.
Publicado: (2015)

Enfuvirtide antiretroviral therapy in HIV-1 infection
por: Kitchen, Christina MR, et al.
Publicado: (2008)

Effectiveness and Risk Factors for Virological Outcome of Raltegravir-Based Therapy for Treatment-Experienced HIV-Infected Patients
por: Mata-Marín, José Antonio, et al.
Publicado: (2017)

Enfuvirtide in therapy at patients with HIV-infection and tuberculosis
por: Kravchenko, AV, et al.
Publicado: (2010)

Prevalence of HIV drug-resistance mutations in HIV-infected Mexican patients heavily experienced to antiretroviral therapy
por: Gaytán-Martínez, JE, et al.
Publicado: (2010)

Fusion inhibitors and their evolving role during salvage antiretroviral therapy. Seven years of experience with enfuvirtide
por: Manfredi, Roberto
Publicado: (2010)

Metabolic, mitochondrial, renal and hepatic safety of enfuvirtide and raltegravir antiretroviral administration: Randomized crossover clinical trial in healthy volunteers
por: Barroso, Sergio, et al.
Publicado: (2019)

Enfuvirtide biosynthesis in thermostable chaperone-based fusion
por: Zenin, Vladimir, et al.
Publicado: (2022)

Strong correlation between protein reagent strip and protein-to-creatinine ratio for detection of renal dysfunction in HIV-infected patients: a cross-sectional study
por: López De León, José Ignacio, et al.
Publicado: (2015)

Synergistic anti-HIV-1 activity of griffithsin with tenofovir, maraviroc and enfuvirtide
por: Férir, Geoffrey, et al.
Publicado: (2011)

Massively Parallel Profiling of HIV-1 Resistance to the Fusion Inhibitor Enfuvirtide
por: Dingens, Adam S., et al.
Publicado: (2019)

Modulations of human placental transfer of lopinavir, ritonavir and enfuvirtide
por: Ceccaldi, Pierre-François, et al.
Publicado: (2010)

Risk factors associated with mortality in patients infected with influenza A/H1N1 in Mexico
por: Mata-Marín, Luis Alberto, et al.
Publicado: (2015)

HIV-1 Fusion Inhibitor Peptides Enfuvirtide and T-1249 Interact with Erythrocyte and Lymphocyte Membranes
por: Matos, Pedro M., et al.
Publicado: (2010)

Enfuvirtide−PEG conjugate: A potent HIV fusion inhibitor with improved pharmacokinetic properties
por: Cheng, Shuihong, et al.
Publicado: (2016)

Sphingopeptides: dihydrosphingosine‐based fusion inhibitors against wild‐type and enfuvirtide‐resistant HIV‐1
por: Ashkenazi, Avraham, et al.
Publicado: (2012)

Assessment of Antibody Interference of Enfuvirtide (T20) Function Shows Assay Dependent Variability
por: Smith, Michele, et al.
Publicado: (2018)

A Blast From the Past: Abdominal Wall Amyloidosis Due to Enfuvirtide Injections
por: Costiniuk, Cecilia, et al.
Publicado: (2023)

Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial
por: de Castro, Nathalie, et al.
Publicado: (2016)

High prevalence of genotype G in HIV co-infected patients compared with HBV monoinfected patients in México
por: Mata-Marín, JA, et al.
Publicado: (2010)

Short-course intensification with enfuvirtide in virologic failure: impact on intracellular HIV reservoir and on viral tropism (INNOVE study)
por: Ghosn, J, et al.
Publicado: (2010)

In Vitro Selection and Characterization of HIV-1 Variants with Increased Resistance to LP-40, Enfuvirtide-Based Lipopeptide Inhibitor
por: Hu, Yue, et al.
Publicado: (2022)

Thermostable chaperone-based polypeptide biosynthesis: Enfuvirtide model product quality and protocol-related impurities
por: Zenin, Vladimir, et al.
Publicado: (2023)

A Novel Class of Anti-HIV Agents with Multiple Copies of Enfuvirtide Enhances Inhibition of Viral Replication and Cellular Transmission In Vitro
por: Chang, Chien-Hsing, et al.
Publicado: (2012)

Characterization of Gp41 Polymorphisms in the Fusion Peptide Domain and T-20 (Enfuvirtide) Resistance-Associated Regions in Korean HIV-1 Isolates
por: Jang, Dai-Ho, et al.
Publicado: (2014)

Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy
por: Zhu, Xiaojie, et al.
Publicado: (2015)

HIV integrase variability and genetic barrier in antiretroviral naïve and experienced patients
por: Piralla, Antonio, et al.
Publicado: (2011)

Development of a HPLC fluorometric method for the quantification of enfuvirtide following in vitro releasing studies on thermosensitive in situ forming gel
por: Li, Huanhuan, et al.
Publicado: (2023)

Comparison of Cryptococcal Antigenemia between Antiretroviral Naïve and Antiretroviral Experienced HIV Positive Patients at Two Hospitals in Ethiopia
por: Beyene, Tafese, et al.
Publicado: (2013)

Impact of the HIV-1 env Genetic Context outside HR1–HR2 on Resistance to the Fusion Inhibitor Enfuvirtide and Viral Infectivity in Clinical Isolates
por: Baatz, Franky, et al.
Publicado: (2011)

The improved efficacy of Sifuvirtide compared with enfuvirtide might be related to its selectivity for the rigid biomembrane, as determined through surface plasmon resonance
por: Cao, Ping, et al.
Publicado: (2017)

Experiencing antiretroviral adherence: helping healthcare staff better understand adherence to paediatric antiretrovirals
por: Phelps, Benjamin R, et al.
Publicado: (2010)

T20QoL: an observational multicenter cohort study to evaluate the quality of life in HIV-patients treated with enfuvirtide (ENF, T-20) in combination with an optimized background therapy
por: Bucciardini, R, et al.
Publicado: (2008)

Molecular epidemiology of antiretroviral resistance in therapy-experienced HIV-1 patients in Cuba (2009)
por: Pérez, L, et al.
Publicado: (2010)

Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV
por: Guaraldi, Giovanni, et al.
Publicado: (2021)

Adults Experiencing Homelessness in the US–Mexico Border Region: A Photovoice Project
por: Moya, Eva Margarita, et al.
Publicado: (2017)

Mutations Related to Antiretroviral Resistance Identified by Ultra-Deep Sequencing in HIV-1 Infected Children under Structured Interruptions of HAART
por: Vazquez-Guillen, Jose Manuel, et al.
Publicado: (2016)

557. Evaluation of Clinical Response of a Two Tablet Once Daily Antiretroviral Regimen in Antiretroviral Experienced HIV-Infected Patients
por: Maki, Gina, et al.
Publicado: (2018)

Duration of antiretroviral regimens in treatment-experienced patients in clinical practice
por: Vilaplana, Vicente Escudero, et al.
Publicado: (2010)

Opistobranquios de México : guía de babosas marinas del pacífico, Golfo de California y las islas oceanicas /
por: Hermosillo, Alicia
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_q7sd9elju9ksbhld7hchgaf2d2